Apogee Therapeutics, Inc. (APGE) Form 10-Q — Aug 10, 2026
Apogee Therapeutics' fiscal Q2 2026 10-Q shows the clinical-stage biotech posted a net loss of $85.9 million for the quarter and $160.0 million for the first six months of 2026, with no product revenue since inception. It ended June 30, 2026 with $105.6 million in cash and roughly $1.3 billion in total cash and marketable securities, which management expects to fund operations through at least the next 12 months. The filing is dominated by the pending merger with AbbVie: Apogee signed the Merger Agreement on June 18, 2026, and disclosed that the HSR Act waiting period expired on August 5, 2026, satisfying a key closing condition, with German and Austrian antitrust clearances already secured.
Key figures
- Total Debt
- 99231000
- Debt Amount
- 100000000
- Total Assets
- 1335813000
- Cash Position
- 105571000
- Runway
- at least 12 months
- Accumulated deficit
- 721724000
- Merger termination fee
- 381273716
- Revenue share liability
- 99231000
- Marketable securities current
- 866355000
- Shares outstanding aug 3 2026
- 75687735
- Marketable securities long term
- 321943000
- Revenue share effective interest rate
- 16.4%
Price after filing
Close on the filing date to close N calendar days later (from $134.84). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.